Purchase this article with an account.
O. Roche, F. Suarez, J. Rozet, J. Kaplan, H. Dollfus, O. Hermine, J.-L. Dufier; Erythropoietin Therapy in a Patient Suffering From Retinitis Pigmentosa and Sideroblastic Anemia. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2179. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report a patient with severe RP leading to blindness who was treated with rEpo for an associated congenital sideroblastic anemia.
A 19-year-old male with Bardet-Biedl syndrome that included a classical, bilateral pigmentary retinopathy with secondary blindness, was treated with recombinant erythropoietin for an associated congenital sideroblastic anemia.
During the 12-month follow-up, there was a dramatic improvement of the visual acuity (20/2000 to 20/50), visual fields and retinal electrophysiological activity as well as an increase of the retinal thickness, while hematological parameters remained unchanged.
rEpo treatment had no effect on the Hb level but was followed by a dramatic improvement of visual acuity and objective ophtalmologic parameters suggesting a direct effect of Epo on the retina.This provocative case report supports the concept that erythropoietin may act as a retinal growth factor and may be of benefit to a subset of patients with retinitis pigmentosa.
This PDF is available to Subscribers Only